Oral involvement by Stevens-Johnson Syndrome associated with carbamazepine in an immunosuppressed patient
Case report
DOI:
https://doi.org/10.5935/2525-5711.20230217Keywords:
Hypersensitivity, Drug Hypersensitivity, Stevens-Johnson Syndrome, Carbamazepine, Mouth MucosaAbstract
INTRODUCTION: Stevens-Johnson syndrome (SJS) is caused by a delayed immune response triggered by the association of genetic and environmental factors. This reaction can be mediated mainly by some drugs.
OBJECTIVE: The purpose of this article is to report the case of a patient with SJS associated with carbamazepine.
CASE REPORT: A man was hospitalized complaining of odynophagia, whitish plaques in the mouth and swelling of the lips. Clinical examination revealed ulcerated and erosive lesions involving the buccal mucosa, lips, tongue and hard palate. The lips were swollen and with hemorrhagic crusts. Papular and purplish-colored lesions were observed on the skin. The patient reported that the lesions started 10 days ago, coinciding with the start of carbamazepine use. The diagnosis of SJS was established based on clinical information and the patient treated with support therapy.
CONCLUSION: SJS is a clinical condition that affects the oral mucosa and can be triggered by the use of carbamazepine.
References
Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9:F1000.
Lerch M, Mainetti C, Beretta-Piccoli BT, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018 Feb;54(1):147-6.
Emerick MFB, Rodrigues MMT, Pedrosa DMAS, Novaes MRCG, Gottems LBD. Síndrome de Stevens-Johnson e necrólise epidérmica tóxica em um hospital do Distrito Federal. Rev Bras Enferm. 2014 Dec;67(6):898-904.
Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015;13(7):625-45.
Al Rajaibi R, Al Rumhi T, Al Abri AM. Carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap treated successfully with oral cyclosporin: case report and literature review. Sultan Qaboos Univ Med J. 2021 Aug;21(3):491-4.
Khalid K, Kwak BS, Leo RJ. Oxcarbazepine-induced Stevens-Johnson syndrome. Prim Care Companion CNS Disord. 2018 Dec;20(6):18l02304.
Guleria VS, Sharda C, Rana T, Sood AK. Oxcarbazepine induced toxic epidermal necrolysis - a rare case report. Indian J Pharmacol. 2015 Jul/Aug;47(4):459-61.
Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010 Dec;5:39.
Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1039-58.
Bulisani ACP, Sanches GD, Guimarães HP, Lopes RD, Vendrame LS, Lopes AC. Síndrome de Stevens-Johnson e necrólise epidérmica tóxica em medicina intensiva. Rev Bras Ter Intensiva. 2006;18(3):292-7.
Dutt J, Sapra A, Sheth-Dutt P, Bhandari P, Gupta S. Stevens-Johnson syndrome: a perplexing diagnosis. Cureus. 2020 Mar;12(3):e7374.
Trivedi BS, Darji NH, Malhotra SD, Patel PR. Antiepileptic drugs-induced Stevens-Johnson syndrome: a case series. J Basic Clin Pharm. 2016;8(1):42-4.
Ambrósio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002 Feb;27(1-2):121-30.
Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009 Nov/Dec;75(6):579-82.
Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011 Feb;50(2):221-4.
Hirapara HN, Patel TK, Barvaliya MJ, Tripathi C. Drug-induced Stevens-Johnson syndrome in Indian population: a multicentric retrospective analysis. Niger J Clin Pract. 2017 Aug;20(8):978-83.
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002 Mar;359(9308):727-32.
Bakshi SS. Stevens-Johnson syndrome. Intern Emerg Med. 2019;14(2):323-4.
Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986 Nov;204(5):503-12.
Thakur V, Vinay K, Kumar S, Choudhary R, Kumar A, Parsad D, et al. Factors predicting the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis: a 5-year retrospective study. Indian Dermatol Online J. 2021 Mar;12(2):258-65.
Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004 Nov;279(47):48487-90.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jean Teruo Hamasaki, Marcelo Morato, Rosana Camargo, Antonio Adilson Soares de Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
